Spyre Therapeutics, Inc. SYRE
Spyre Therapeutics, Inc. (Nasdaq: SYRE) is an immunology/inflammation drug developer. Its lead program, SKYLINE (SPY001, SPY002, SPY003 and combinations), is in Phase 2 for Ulcerative colitis. Its next catalyst on record is SPY072 (anti-TL1A): SKYWAY PsA and axSpA sub-study topline data expected 4Q 2026; SPY003 SKYLINE Part A UC data September 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SPY072 (anti-TL1A) — SKYWAY PsA and axSpA sub-study topline data expected 4Q 2026; SPY003 SKYLINE Part A UC data September 2026. (Q4 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SPY001 / SPY002 / SPY003 (SKYLINE) | Ulcerative colitis | antibody | Phase 2 |
| SPY072 (SKYWAY) | Rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis | antibody | Phase 2 |
Recent results and decisions
- Sep 8, 2026met SPY003 met primary endpoint: RHI reduction of 10.0 points at Week 12 (p<0.0001); clinical remission 20%, endoscopic improvement 30% (open-label, n=44).
SPY003 achieved the primary endpoint, demonstrating a statistically significant 10.0-point reduction in RHI score (p<0.0001)
Filing - Aug 25, 2026mixed Randomized RA sub-study: low dose significantly beat placebo on primary DAS28-CRP (-1.9 vs -1.3, p<0.05), high dose did not (-1.5); company says results did not meet its internal bar to advance SPY072 as RA monotherapy.
SPY072 Low Dose demonstrated a statistically significant benefit compared to placebo on the primary endpoint (change from baseline in DAS28-CRP) at Week 12.
Filing - Jun 15, 2026met SPY002 met primary endpoint: RHI reduction of 10.7 points at Week 12 (p<0.0001); clinical remission 33%, endoscopic improvement 42% (open-label, n=48).
SPY002 achieved the primary endpoint, demonstrating a statistically significant 10.7-point reduction in RHI score (p<0.0001)
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.